CureVac (Group)

https://www.curevac.com

CureVac (Nasdaq: CVAC) is a global biopharmaceutical company in the field of messenger RNA (mRNA) technology, with more than 20 years of expertise in developing, optimizing, and manufacturing this versatile biological molecule for medical purposes. The principle of CureVac’s proprietary technology is the use of optimized mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a broad range of diseases. In July 2020, CureVac entered in a collaboration with GSK to jointly develop new products in prophylactic vaccines for infectious diseases based on CureVac’s second-generation mRNA technology. This collaboration was later extended to the development of second-generation COVID-19 vaccine candidates, and modified mRNA vaccine technologies. Based on its proprietary technology, CureVac has built a deep clinical pipeline across the areas of prophylactic vaccines, cancer therapies, antibody therapies, and the treatment of rare diseases. CureVac N.V. has its headquarters in Tübingen, Germany, and has more than 1,100 employees across its sites in Germany, the Netherlands, Belgium, Switzerland and the U.S. *

	Start	2000-08-01 established
	Predecessor	University of Tübingen (Eberhard-Karls-Universität)
	Industry	RNAi technology
	Industry 2	RNActive® vaccination technology
	Person	Zehnder, Alexander (CureVac 202304– CEO before Sanofi + Roche/Genetech)
	Person 2	Stéphenne, Jean (GSK Biologicals 200512 President)

	Region	Tübingen
	Country	Germany
	Street	15 Friedrich-Miescher-Str.
	City	72076 Tübingen
	Tel	+49-7071-92053-0
		Address record changed: 2024-01-05

Basic data	Employees	F: 1,001 to 5,000 (2023-12-31)
	Currency	EUR
	Annual sales	53,738,000 (revenue, annual, consolidated (2023) 2023-12-31)
	Profit	-260,167,000 (2023-12-31)
	Cash	478,381,000 (2023-12-31)

		* Document for »About Section«: CureVac N.V.. (7/14/23). "Press Release: CureVac Announces Update to the Management Team". Tübingen & Boston, MA.

		Record changed: 2024-06-25